Marksans Pharma Limited
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
What Marksans files
- Others46
- Updates43
- Investor Meet28
- Important12
- Board Meeting12
- PPTs7
Marksans Pharma received an ESG score of 56 from Crisil ESG Ratings & Analytics for Fiscal 2026. This score reflects the company's environmental, social, and governance performance based on public data.
Marksans Pharma delivered record quarterly profitability with PAT up 174% to ₹159 Cr and EBITDA rising 113% to ₹213 Cr. Cash crossed ₹1,000 Cr. UK & Europe revenue hit a high of ₹356 Cr, with acquisitions QliniQ and ABCnow bolstering European expansion.
Marksans Pharma has completed the acquisition of 100% share capital of Germany-based ABCnow GmbH. This strategic move strengthens the company's operational footprint.
Marksans Pharma launched its "Saksham Niveshak" campaign to assist shareholders in claiming past unclaimed dividends and updating KYC details. This initiative aims to empower investors by preventing fund transfers to IEPF and ensuring updated records for direct processing.
Marksans Pharma acquires 100% of Germany's ABCnow GmbH for €892,384. This strategic move expands Marksans' presence in regulated European markets, gaining direct distribution and sales capabilities for its products.